Souberbielle JC, Body JJ, Lappe JM et al (2010) Vitamin D and musculoskeletal health,

cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 9:709–715PubMed 117. Pazianas M, Cooper C, Ebetino FH, Russell RG (2010) Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 6:325–343PubMed 118. Green JR, Rogers M (2002) Pharmacological profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug OICR-9429 concentration Dev Res 55:210–224 119. Papapoulos SE, Cremers SC (2007) Prolonged bisphosphonate release after treatment in children. N Engl J Med 356:1075–1076PubMed 120. McNicholl DM, Heaney LG (2010) The safety of bisphosphonate use in pre-menopausal women on corticosteroids. Curr Drug Saf 5:182–187PubMed 121. Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386–392PubMed 122. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D (1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates

treatment in vitro and in patients with malignancy. Bone 18:133–139PubMed 123. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid selleck screening library and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101–111PubMed Fossariinae 124. Miller PD, McClung MR, Macovei L et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE

study. J Bone Miner Res 20:1315–1322PubMed 125. 17-AAG datasheet Recker RR, Lewiecki EM, Miller PD, Reiffel J (2009) Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 122:S22–32PubMed 126. Thompson K, Rogers MJ (2004) Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 19:278–288PubMed 127. Srivastava T, Haney CJ, Alon US (2009) Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res 24:334–337PubMed 128. Reid DM, Devogelaer JP, Saag K et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263PubMed 129. Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, Zanatta M, Valenti MT, Dalle Carbonare L, Lo Cascio V (2010) Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 25:447–454PubMed 130.